Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

References

• European Glaucoma Society (EGS)Terminology and Guidelines for Glaucoma4th editionSavona, ItalyPublicomm2014140
   Google Scholar
• LundbergLUThygesonJDamgard-JensenLGlaucoma patients treated by practicing ophthalmologists in Denmark. Estimated number of patients and the extend of visual field defectsUgeskr Laeger20001623028303310850191
   PubMedGoogle Scholar
• SchwabeUPaffrathDPrescription report for pharmaceuticals 2011Actual data, cost, trends and commentaries [Arzneiverordnungs-Report 2011 Aktuelle Daten, Kosten, Trends und Kommentare] in GermanHeidelberg, GermanySpringer2012770778
   Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• HigginbothamEJConsiderations in glaucoma therapy: fixed combinations versus their component medicationsClin Ophthalmol201041920169043
   PubMedGoogle Scholar
• HigginbothamEJHansenJDavisEJWaltJGGuckianAGlaucoma medication persistence with a fixed combination versus multiple bottlesCurr Med Res Opin200925102543254719731993
   PubMed Web of Science ®Google Scholar
• KonstasAGHollóGPreservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucomaExpert Opin Pharmacother20161791271128327123557
   PubMed Web of Science ®Google Scholar
• HoySMTafluprost/Timolol: a review in open-angle glaucoma or ocular hypertensionDrugs201575151807181326431840
   PubMed Web of Science ®Google Scholar
• HollóGHommerAAntón LópezARopoAEfficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredientsJ Ocul Pharmacol Ther201430646847524738883
   PubMed Web of Science ®Google Scholar
• PfeifferNTraversoCELorenzKA 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free componentsAdv Ther201431121228124625447269
   PubMed Web of Science ®Google Scholar
• BaudouinCLabbéALiangHPreservatives in eyedrops: the good, the bad and the uglyProg Retin Eye Res201029431233420302969
   PubMed Web of Science ®Google Scholar
• BaudouinCDetrimental effect of preservatives in eyedrops: implications for the treatment of glaucomaActa Ophthalmol200886771672618537937
   PubMed Web of Science ®Google Scholar
• BaudouinCLiangHHamardPThe ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathwaysOphthalmology2008115110911517532048
   PubMed Web of Science ®Google Scholar
• NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther200118520521511783457
   PubMed Web of Science ®Google Scholar
• RasmussenCAKaufmanPLKilandJABenzalkonium chloride and glaucomaJ Ocul Pharmacol Ther2014302–316316924205938
   PubMed Web of Science ®Google Scholar
• KahookMYNoeckerRQuantitative analysis of conjunctival goblet cells after chronic application of topical dropsAdv Ther200825874375118670744
   PubMed Web of Science ®Google Scholar
• JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol200717334134917534814
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
   PubMed Web of Science ®Google Scholar
• NordmannJPAuzanneauNRicardSBerdeauxGVision related quality of life and topical glaucoma treatment side effectsHealth Qual Life Outcomes200317514667241
   PubMedGoogle Scholar
• HollóGVuorinenJTuominenJHuttunenTRopoAPfeifferNFixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination productsAdv Ther201431993294425213118
   PubMed Web of Science ®Google Scholar
• ChunMGracitelliCPLopesFSBiteliLGUshidaMPrataTSSelective laser trabeculoplasty for early glaucoma: analysis of success predictors and adjusted laser outcomes based on the untreated fellow eyeBMC Ophthalmol201616120627881155
   PubMed Web of Science ®Google Scholar
• PillunatKRSpoerlEElfesGPillunatLEPreoperative intraocular pressure as a predictor of selective laser trabeculoplasty efficacyActa Ophthalmol201694769269627213294
   PubMed Web of Science ®Google Scholar
• CordeiroMFGoldbergISchiffmanRBernsteinPBejanianMEfficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients versus previously treated patientsClin Ophthalmol201591605161126357461
   PubMedGoogle Scholar
• GoldbergIPinaRGLanzagorta-ArestiASchiffmanRMLiuCBejanianMBimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trialBr J Ophthalmol201498792693124667994
   PubMed Web of Science ®Google Scholar
• RobinALCovertDDoes adjunctive glaucoma therapy affect adherence to the initial primary therapy?Ophthalmology2005112586386815878067
   PubMed Web of Science ®Google Scholar
• RobinALNovackGDCovertDWCrockettRSMarcicTSAdherence in glaucoma: objective measurements of once-daily and adjunctive medication useAm J Ophthalmol2007144453354017686450
   PubMed Web of Science ®Google Scholar
• SchnoberDHubatschDAScherzerMEfficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapyClin Ophthalmol2015982583226005326
   PubMed Web of Science ®Google Scholar
• NoeckerRJHerrygersLAAnwaruddinRCorneal and conjunctival changes caused by commonly used glaucoma medicationsCornea200423549049615220734
   PubMed Web of Science ®Google Scholar
• MartoneGFrezzottiPTosiGMAn in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphologyAm J Ophthalmol2009147472573519181302
   PubMed Web of Science ®Google Scholar
• VaedeDBaudouinCWarnetJMBrignole-BaudouinFPreservatives in eye drops: toward awareness of their toxicityJ Fr Ophthalmol2010337505524 French
   Web of Science ®Google Scholar
• BaudouinCDenoyerADesbenoitNHammGGriseAIn vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis)Trans Am Ophthalmol Soc2012110406323818734
   PubMedGoogle Scholar
• DesbenoitNSchmitz-AfonsoIBaudouinCLocalisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometryAnal Bioanal Chem2013405124039404923430186
   PubMed Web of Science ®Google Scholar
• AmmarDAKahookMYEffects of benzalkonium chloride-or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cellsMol Vis2011171806181321750606
   PubMed Web of Science ®Google Scholar
• LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma200817535035518703943
   PubMed Web of Science ®Google Scholar
• ErbCGastUSchremmerDGerman register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eyeGraefes Arch Clin Exp Ophthalmol2008246111593160118648841
   PubMed Web of Science ®Google Scholar
• HollóGKatsanosASafety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucomaExpert Opin Drug Saf201514460961725640746
   PubMed Web of Science ®Google Scholar